492 results on '"Harada, Taishi"'
Search Results
2. Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
3. Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy
4. Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer
5. Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
6. A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
7. Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study
8. TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study
9. Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
10. A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
11. Microbiological analysis of patients with first and recurrent episodes of acute cholangitis in a middle-sized hospital: A single-center retrospective study in rural North Kyoto, Japan
12. A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non‐small cell lung cancer (LOGIK1902).
13. A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L)
14. Study of factors related to recurrence within 30 days after pneumonia treatment for community-onset pneumonia
15. Intrathecal Trastuzumab for HER2-Positive Cancer of Unknown Primary Leptomeningeal Metastasis: A Case Report
16. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer
17. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
18. Procalcitonin-Guided Antibiotic Discontinuation Might Shorten the Duration of Antibiotic Treatment Without Increasing Pneumonia Recurrence
19. A Case of Bronchobiliary Fistula Successfully Treated for Bronchial Occlusion Using Endobronchial Watanabe Spigot and Embolization Coils
20. Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study)
21. Malignant Transformation of Unknown Duration of an Ovarian Mature Cystic Teratoma Presenting as a Trocar Recurrence in a Young Patient: A Case Report and Literature Review
22. Anti-EJ antibody-positive interstitial pneumonia with breast cancer improved by combining immunosuppressive therapy and chemotherapy
23. Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry
24. A Phase II Single-Arm Study of Osimertinib for Radiotherapy-Naive CNS Metastasis Non-Small Cell Lung Cancer: Results for the First-line cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
25. Five-year follow up analysis of Japanese ILD registry
26. Study of the usefulness of small-bore aspiration catheters (Aspiration Kit®) for treating pneumothorax
27. Comprehensive analysis of prognostic factors in hospitalized patients with pneumonia occurring outside hospital: Serum albumin is not less important than pneumonia severity assessment scale
28. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
29. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
30. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer
31. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
32. Procalcitonin is not an independent predictor of 30-day mortality, albeit predicts pneumonia severity in patients with pneumonia acquired outside the hospital
33. Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).
34. Resection of tracheal mucosa‐associated lymphoid tissue ( MALT ) lymphoma by bronchoscopic high‐frequency electrosurgical snare: Case report
35. Data from Role and Relevance of TrkB Mutations and Expression in Non–Small Cell Lung Cancer
36. Supplementary Figure S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
37. Supplementary Table S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
38. Supplementary Data from Role and Relevance of TrkB Mutations and Expression in Non–Small Cell Lung Cancer
39. Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
40. Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non–small-cell lung cancer
41. High levels of AXL expression in untreatedEGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
42. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer
43. A case of adult multisystem Langerhans histiocytosis successfully treated by smoking cessation and radiotherapy for bone lesion
44. Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy.
45. Anaplastic carcinoma of the pancreas diagnosed by endoscopic ultrasound-guided fine-needle aspiration: a case report and review of the literature
46. Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study
47. Elevation of serum C-reactive protein predicts failure of the initial antimicrobial treatment for febrile neutropenia with lung cancer
48. Post-treatment PET–CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass
49. Rapid decrease in forced vital capacity in patients with idiopathic pulmonary upper lobe fibrosis
50. Advanced atypical lung carcinoid tumour successfully treated with carboplatin, etoposide and atezolizumab: A case report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.